Zoetis에 대한 매도 수량은 투자자에게 Zoetis의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Zoetis (NYSE:ZTS) 주식, 공매도 수량 보고

Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

Zoetis Inc

Ztest Electronics Inc

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 4.24% on an annualized basis producing an average annual return of 15.83%. Currently, Zoetis has a market capitalization of $80.69 billion. 
Buying $100 In ZTS: If an investor had bought $100 of ZTS stock 10 years ago, it would be worth $437.80 today based on a price of $178.84 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734039012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

The Q1 dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 21, 2025.

Dividends

Zoetis Boosts Quarterly Dividend By 16% From $0.432 To $0.50 Per Share

UBS initiates coverage on Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Neutral rating and announces Price Target of $196.

Price Target

Initiation

UBS Initiates Coverage On Zoetis with Neutral Rating, Announces Price Target of $196

Barclays analyst Balaji Prasad maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and raises the price target from $230 to $242.

Barclays Maintains Overweight on Zoetis, Raises Price Target to $242

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on MediciNova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) with a Buy rating and announced a price target of $9. MediciNova shares closed at $2.07 on Friday. See how other analysts view this stock.</li>
<li>Morgan Stanley analyst Patrick Wood initiated coverage on PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) with an Overweight rating and announced a price target of $105. PROCEPT BioRobotics shares closed at $95.59 on Friday. <a href="https://www.benzinga.com/quote/PRCT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Biren Amin initiated coverage on Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with an Overweight rating and announced a price target of $74. Viking Therapeutics shares closed at $52.94 on Friday. <a href="https://www.benzinga.com/quote/VKTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst Taylor McGinnis initiated coverage on Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy rating and announced a price target of $350. Autodesk shares closed at $291.90 on Friday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Daniel Clark initiated coverage on Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with an Outperform rating and announced a price target of $215. Zoetis shares closed at $175.25 on Tuesday. <a href="https://www.benzinga.com/quote/ZTS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ADSK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3-1024x544.png" alt="" class="wp-image-672368" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/02085443/image-1-3.png 1187w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/12/42265024/how-to-earn-500-a-month-from-marvell-technology-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Marvell Technology Stock Ahead Of Q3 Earnings</a></li>
</ul>

Pre-Market Outlook

Markets

ADSK

MNOV

PRCT

VKTX

This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Leerink Partners analyst Daniel Clark initiates coverage on Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Outperform rating and announces Price Target of $215.

Leerink Partners Initiates Coverage On Zoetis with Outperform Rating, Announces Price Target of $215

In a new SEC filing on November 26, it was revealed that Polzer, Executive Vice President at Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), executed a significant exercise of company stock options.
What Happened: The latest Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001555280/000155528024000339//Archives/edgar/data/1555280/000155528024000339/0001555280-24-000339-index.htm">U.S. Securities and Exchange Commission</a> uncovered Polzer, Executive Vice President at Zoetis, exercising stock options for 3,477 shares of ZTS. The total transaction was valued at $227,809.
During Wednesday's morning session, Zoetis shares up by 1.49%, currently priced at $178.32. Considering the current price, Polzer's 3,477 shares have a total value of $227,809.
<h3>Delving into Zoetis's Background</h3>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Breaking Down Zoetis's Financial Performance</h3>
Revenue Growth: Zoetis's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.02%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 70.64%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Zoetis's EPS is below the industry average. The company faced challenges with a current EPS of 1.51. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 1.29, Zoetis adopts a prudent financial strategy, indicating a balanced approach to debt management.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 33.03 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 8.78 is above industry norms, reflecting an elevated valuation for Zoetis's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 22.28, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001555280">Check Out The Full List Of Zoetis's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Robert Polzer Exercises Options, Realizes $227K

Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes <a href="https://www.benzinga.com/topic/2024-election">for the 47th president.</a>
Betting markets leaned slightly toward Donald Trump, with CFTC-regulated Kalshi placing Trump's win probability at 56% compared to Kamala Harris's 44%.
National polls show a close contest, with the latest New York Times/Siena College poll indicating both candidates tied at 48% in the popular vote.
The S&amp;P 500 climbed 1.2%, while the tech-focused Nasdaq 100 surged 1.5%, marking its strongest one-day increase in nearly a month. 
All 11 sectors of the S&amp;P 500 experienced gains, with consumer discretionary stocks outperforming. Small caps also joined the rally, with the Russell 2000 index gaining 1.1%.
Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) led the S&amp;P 500, with shares soaring after the artificial intelligence company surpassed quarterly earnings estimates and provided strong guidance.
In macroeconomic news, U.S. services sector activity hit over two-year highs <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41750522/us-services-sector-gauge-rises-more-than-expected-to-over-2-year-highs-as-employm">in October, outperforming expectations</a>.
Treasury yields increased by 5 basis points, while the dollar declined for a second consecutive session.
Gold edged up 0.3%, hovering near record highs, and oil prices gained 1.2% after a 3.2% surge on Monday.
Crypto sentiment was strong as well, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) jumping 4.5% to over $70,000 and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) spiking 12%.
Read also: <a href="https://www.benzinga.com/markets/24/11/41741466/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a>
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,259.62</td>
<td>1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,779.38</td>
<td>1.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,244.40</td>
<td>1.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,191.93</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.1% to $575.87.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.9% to $421.79.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 1.4% to $492.61.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $222.47.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 1.7%. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, up 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), up 4.8%</li>
<li>Palantir Technologies Inc., up 22.8%</li>
<li>NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), down 6.8%</li>
<li>Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), down 1.6%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), down 2.3%</li>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), down 0.5%</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), up 6.2%</li>
<li>Emerson Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>), up 6.8%, </li>
<li>Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), up 3.9%, </li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>), up 8.8%, </li>
<li>Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>), 4.7%,</li>
<li>YUM! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), up 2.5%, </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: &#8216;Bond Vigilantes Have Been Voting Early&#8217;</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Politics

Economics

Tech

ETFs

$BTC

$DOGE

SPDR Dow Jones Industrial Average ETF Trust

FANG

ILMN

NXPI

PLTR

TRGP

VRTX

Select Sector SPDR-Consumer Discretionary

YUMC

Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.00</td>
<td>$44.7K</td>
<td>552</td>
<td>2.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$19.00</td>
<td>$57.0K</td>
<td>804</td>
<td>1.7K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$40.6K</td>
<td>292</td>
<td>866</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$210.00</td>
<td>$32.3K</td>
<td>1.6K</td>
<td>719</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$120.00</td>
<td>$142.8K</td>
<td>2.9K</td>
<td>504</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$800.00</td>
<td>$26.5K</td>
<td>379</td>
<td>274</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$232.6K</td>
<td>1.5K</td>
<td>235</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$55.0K</td>
<td>368</td>
<td>155</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$285.00</td>
<td>$34.5K</td>
<td>428</td>
<td>155</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$365.00</td>
<td>$53.5K</td>
<td>215</td>
<td>108</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ALLK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>), we observe a call option sweep with bullish sentiment. It expires in 45 day(s) on December 20, 2024. Parties traded 819 contract(s) at a $1.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $44.7K, with a price of $55.0 per contract. There were 552 open contracts at this strike prior to today, and today 2319 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 300 contract(s) at a $19.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $57.0K, with a price of $190.0 per contract. There were 804 open contracts at this strike prior to today, and today 1754 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 58 contract(s) at a $45.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $40.6K, with a price of $700.0 per contract. There were 292 open contracts at this strike prior to today, and today 866 contract(s) were bought and sold. 
• Regarding ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we observe a call option sweep with bearish sentiment. It expires in 73 day(s) on January 17, 2025. Parties traded 719 contract(s) at a $210.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $32.3K, with a price of $45.0 per contract. There were 1601 open contracts at this strike prior to today, and today 719 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 340 contract(s) at a $120.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $142.8K, with a price of $420.0 per contract. There were 2969 open contracts at this strike prior to today, and today 504 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bullish sentiment. It expires in 10 day(s) on November 15, 2024. Parties traded 15 contract(s) at a $800.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $1773.0 per contract. There were 379 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 227 contract(s) at a $50.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $232.6K, with a price of $1025.0 per contract. There were 1525 open contracts at this strike prior to today, and today 235 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 163 day(s) on April 17, 2025. Parties traded 77 contract(s) at a $65.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.0K, with a price of $715.0 per contract. There were 368 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 10 day(s) on November 15, 2024. This event was a transfer of 75 contract(s) at a $285.00 strike. The total cost received by the writing party (or parties) was $34.5K, with a price of $460.0 per contract. There were 428 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 104 contract(s) at a $365.00 strike. This particular call needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $515.0 per contract. There were 215 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALLK

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

10 Health Care Stocks Whale Activity In Today's Session

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 4.08% on an annualized basis producing an average annual return of 14.89%. Currently, Zoetis has a market capitalization of $79.87 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $4,362.05 today based on a price of $176.29 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730815248_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,400 Today

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of <a href="https://www.benzinga.com/topic/election-day">Election Day on Tuesday</a>. 
Vice President Kamala Harris holds a 1-point lead over ex-President Donald Trump, according to the New York Times national polling average; she has a 4-point lead among likely voters nationally, <a href="https://maristpoll.marist.edu/polls/u-s-presidential-contest-november-2024/">according to the latest PBS News/NPR/Marist poll</a>.
Betting markets, as tracked by the CFTC-regulated Kalshi, favor a Trump win at a 53% chance, <a href="https://www.benzinga.com/general/politics/24/11/41702729/harris-surges-in-prediction-markets-nabs-kalshi-lead-with-just-three-days-to-go">but with diminishing odds</a> compared to previous weeks. Also, the betting odds are susceptible to wild swings from so-called "whale" bettors, including one individual on Polymarket <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41463756/polymarket-to-review-user-base-in-light-of-whales-betting-millions-on-trump-election-win" target="_blank" rel="noreferrer noopener">who spent as much as</a> $43 million on a Trump victory.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41717129/polymarkets-all-time-leading-trader-bets-over-500-000-on-kamala-harris-slams-nate-silver-f">Polymarket&#8217;s All-Time Leading Trader Bets Over $500,000 On Kamala Harris, Slams Nate Silver For Including &#8216;Fake Poll&#8217; Data In Model</a>
&#8220;Neither candidate holds a meaningful edge in enough states to win 270 electoral votes. In the history of modern polling, there's never been a race where the final polls showed such a close contest,&#8221; said Nate Cohn, chief political analyst for the New York Times. 
The S&amp;P 500 slipped 0.2%, while the Dow dropped 0.6%, hitting its lowest intraday level since mid-September. In contrast, small-cap stocks in the Russell 2000 outperformed, rising 1%. The Nasdaq 100 also retreated, dipping below the 20,000 mark.
Treasury yields fell by nearly 10 basis points as investors scaled back positions linked to Trump&#8217;s inflationary policies, such as high tariffs and more expansionary fiscal measures. The dollar also weakened, down 0.5%.
The increasing likelihood of a Harris victory gave a boost to solar and renewable energy stocks, with the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) climbing 3.6%. 
Oil and gas stocks also gained, as crude prices surged 3% after OPEC+ postponed an anticipated production hike. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) jumped 3%, marking its largest single-day gain since late June.
Gold held steady at $2,740, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell over 1%, dropping below $68,000.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,230.95</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,715.31</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,978.22</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,807.92</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.1% to $570.22.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.5% to $418.44.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.2% to $486.77.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $221.27.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, rising 1.7%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.5%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), down 3.9%, </li>
<li>Constellation Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NYSE">CEG</a>), down 10.5%, </li>
<li>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), down 1.8%, </li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), down 0.4%, </li>
<li>Public Service Enterprise Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), down 5.9%, </li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), down 5.5%. </li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>), up 3.7%, </li>
<li>YUM China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>), up 7.9%, </li>
<li>Loews Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>), down 4.8%, </li>
</ul>
Stocks slated to report earnings after the close are Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) and Astera Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41702887/harris-takes-lead-in-red-state-iowa-in-shock-poll">Harris Takes Lead In Red State Iowa In Shock Poll</a></li>
</ul>
Image: Shutterstock

Mid Cap

ALAB

HOLX

Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?

On Monday,&nbsp;Zoetis Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) third-quarter 2024 adjusted EPS increased 16% year over year to $1.58, beating the <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">consensus of $1.46</a>.
The animal health firm reported sales of $2.39 billion, up 11%, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41709533/zoetis-announces-third-quarter-2024-results" rel="noreferrer noopener">consensus of $2.29 billion</a>.
On an operational&nbsp;basis, revenue for the third quarter of 2024 increased 14% compared with the third quarter of 2023.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40959456/elancos-dermatology-treatment-secures-fda-approval-for-itchy-dogs-analyst-highlight" rel="noreferrer noopener">Elanco&#8217;s Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy</a>
&#8220;Building on the strong momentum from the first half of the year, we are proud to have delivered another excellent quarter, fueled by our diverse, durable, and science-driven portfolio and our customer obsession that underscore our market leadership,&#8221; said Kristin Peck, Chief Executive Officer of Zoetis.
&#8220;We achieved 15% revenue growth in the U.S. and 13% operational revenue growth internationally, with both our companion animal and livestock portfolios seeing impressive global operational growth, 15% and 11%, respectively.&#8221;
Guidance: Zoetis raised its 2024 revenue guidance to $9.2 billion—$9.3 billion, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40197088/animal-health-firm-zoetis-clocks-strong-q2-earnings-companion-animal-operations-boo" rel="noreferrer noopener">compared to prior guidance</a> of $9.1 billion—$9.25 billion and consensus of $9.194 billion. This is equivalent to an operational growth of 10% %- 11%.
Zoetis raised the 2024 adjusted EPS to $5.86-$5.92 versus prior guidance of $5.78-$5.88 and consensus of $5.82.
The company sees an adjusted net income of $2.67 billion-$2.695 billion, reflecting operational growth of 13.5%-14.5, with a reported net income of net income between $2.435 billion-$2.450 billion.
William Blair writes, &#8220;We view companion animal as the main driver of sentiment for shares and were encouraged to see 15% global growth in the segment despite concerns about competition and end-market noise.&#8221;
The analyst reaffirms an Outperform rating based on Zoetis&#8217;s third-quarter results, which initially appear to support the expectation for double-digit EPS growth in 2025.
Guidance and insights for 2025 provided during 2024 earnings will be the main factor driving valuation growth, William Blair analyst writes.
Price Action: ZTS stock is down 3.88% at $174.86 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" target="_blank" rel="noreferrer noopener">Viking Therapeutics&#8217; Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety</a></li>
</ul>
Photo by huoadg5888 via <a href="https://pixabay.com/photos/pets-cat-dog-animals-mammals-3715733/">Pixabay</a>

Earnings

Guidance

Movers

Zoetis Q3 Earnings Beat, Companion Animal Segment Growth Gives Confidence Into 2025: Analyst

Zoetis shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates.

Zoetis Expects 2024 Adjusted EPS Of $5.86-$5.92 Versus Prior Guidance Of $5.78-$5.88 And Consensus Of $5.82

Zoetis is raising its full year 2024 guidance for revenue and adjusted EPS due to the company's strong first three quarters and the underlying strength in companion animal.
<ul>
<li>Revenue between $9.200 billion to $9.300 billion (operational growth of 10% to 11%)</li>
<li>Reported net income between $2.435 billion to $2.450 billion</li>
<li>Adjusted net income between $2.670 billion to $2.695 billion (operational growth of 13.5% to 14.5%)</li>
<li>Reported diluted EPS of $5.33 to $5.39</li>
<li>Adjusted diluted EPS between $5.86 to $5.92</li>
</ul>

Zoetis Raises 2024 Revenue Guidance Of $9.2B-$9.3B Versus Prior Guidance Of $9.1B-$9.25B And Consensus Of $9.194B

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.46 by 8.22 percent. The company reported quarterly sales of $2.39 billion which beat the analyst consensus estimate of $2.29 billion by 4.36 percent. This is a 11.02 percent increase over sales of $2.15 billion the same period last year.

Zoetis Q3 2024 Adj EPS $1.58 Beats $1.46 Estimate, Sales $2.39B Beat $2.29B Estimate

Kevin O'Leary, better known as Mr. Wonderful from Shark Tank, knows a thing or two about making bets that pay off — especially the crazy ones. In a <a href="https://www.youtube.com/watch?app=desktop&amp;v=8H1GauGOO3k">discussion</a> with Chris Wallace, O'Leary opened up about the unpredictable world of venture investing.
Don't Miss:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
He explained how some of his most bizarre investments, like a company offering genetic testing for cats, turned into massive wins that covered a bunch of other losses. The truth? Venture investing is random, and a lot of it comes down to luck.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I get this one shoved in my face all the time. I'm the only Shark that believed in him! The truth is, venture investing is random. There's a lot of luck involved and you need diversification. <a href="https://t.co/06LyCCK2IJ">pic.twitter.com/06LyCCK2IJ</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1850917130398470260?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Back in 2019, O&#8217;Leary made a seemingly wild bet on Basepaws, <a href="https://www.benzinga.com/startups/24/08/40557261/the-stupid-idea-that-made-kevin-oleary-a-massive-20x-return-it-was-such-a-crazy-pitch-i-bought-it-an">a startup that provides DNA tests for cats</a>. At first glance, it seemed like a quirky, maybe even questionable idea. But Mr. Wonderful went for it anyway. He invested alongside fellow shark Robert Herjavec, each putting in $125,000 for a 5% stake.&nbsp;
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
Fast forward a few years, and Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), a giant in the animal health industry, scooped up Basepaws for well over $50 million. That acquisition meant O'Leary&#8217;s initial investment potentially turned into a 90x return — not bad for something that sounded like a pet gimmick at the start.
"Venture investing is random," O'Leary admitted. "There's a lot of luck in it." For him, diversification is key. O&#8217;Leary explained that, out of the 10-15 deals he makes each year, only a few will end up being big wins, but they're the ones that make all the difference. And often, the winners are the ideas that seem the most unpredictable, like cat DNA tests or a meal-kit service like Plated, which was sold to Albertsons for about $300 million.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
A notable deal that got away from O&#8217;Leary was Ring, the smart doorbell company. He famously passed on Ring when it was pitched on Shark Tank, and it was later sold to Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) for $1 billion. As he told Wallace, &#8220;Thank you for bringing it up Chris. You&#8217;ve ruined my day. I get this one shoved in my face all the time.&#8221;
In a recent <a href="https://www.youtube.com/watch?v=zFCfU9cBIRA">podcast</a>, O&#8217;Leary revealed a fascinating stat — 70% of his returns come <a href="https://www.benzinga.com/startups/24/10/41254217/if-they-say-ive-got-three-kids-i-dont-care-says-kevin-oleary-claims-70-of-his-returns-come-from-wome">from companies led by women</a>. He's found that women entrepreneurs tend to be strong at managing risk, making deliberate choices that help their businesses stay steady even when things get tough. "If you want something done, give it to a busy mother," O&#8217;Leary said, highlighting how balancing multiple responsibilities can make someone a great leader.
To O&#8217;Leary, venture investing is more about taking risks, spreading bets, and understanding that the most unusual concepts can occasionally lead to the greatest returns.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

AMZN

'Venture Investing Is Random,' Says Kevin O'Leary. The Craziest Bets, Like Cat DNA Tests, Often Cover All The Losses

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 6.56% on an annualized basis producing an average annual return of 18.21%. Currently, Zoetis has a market capitalization of $86.12 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,430.67 today based on a price of $190.08 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728932418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Zoetis 10 Years Ago Would Be Worth Today

In the preceding three months, 7 analysts have released ratings for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $213.57, a high estimate of $230.00, and a low estimate of $200.00. Marking an increase of 5.04%, the current average surpasses the previous average price target of $203.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1728658890_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Zoetis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$220.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zoetis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zoetis compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Zoetis's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zoetis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zoetis analyst ratings.</a>
<h2>All You Need to Know About Zoetis</h2>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Zoetis's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Zoetis displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zoetis's net margin is impressive, surpassing industry averages. With a net margin of 26.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Zoetis's ROE stands out, surpassing industry averages. With an impressive ROE of 12.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.38%, the company showcases effective utilization of assets.
Debt Management: Zoetis's debt-to-equity ratio is below the industry average at 1.36, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 7 Analyst Recommendations For Zoetis

The Board of Directors of Zoetis (ZTS) Inc. has declared a dividend of 50c per share for the first quarter of 2025, an increase of 16% from the qua...

Zoetis raises quarterly dividend 16% tot 50c per share

An update from Zoetis ( ($ZTS) ) is now available. Zoetis announced a 16% increase in its quarterly dividend, raising it to $0.500 per share for th...

Zoetis Boosts Dividend by 16% for 2025

Dividend Champion, Contender, And Challenger Highlights: Week Of December 15

Analyst Michael Ryskin of Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report), retaining the price target of $210....

Positive Outlook on Zoetis's Stock Despite FDA Review of Librela

Zoetis dips as FDA cites adverse events linked to canine pain therapy Librela

Zoetis Inc. (ZTS) reported impressive results for the third quarter of 2024, with strong revenue growth across diverse regions. The company's future growth prospects appears promising, fueled by solid demand for its product offerings, operational expansions, and effective capital allocation. So, let's determine whether Zoetis is an ideal addition to your portfolio. Read more to find out... Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>) is the world's leading animal health company, driven to nurture the world and humankind by advancing care for animals. The company reported solid financial results for the third quarter of 2024, posting a record quarterly revenue of $2.39 billion, surpassing analysts' estimate of $2.29 billion. Also, its non-GAAP EPS of $1.58 was above the consensus estimate of $1.46.
The company delivered 14% operational growth in revenue and 15% operational growth in its adjusted net income for the third quarter. Also, its revenue in the U.S. segment was up by 15% from the prior year, totaling $1.35 billion.
ZTS continued to advance its innovation and its efforts towards the care of animals across the globe. The company recently received approval in China for Apoquel&#xAE; Chewable (oclacitinib chewable tablet) for controlling pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs.
It also received approval in the EU for an additional claim related to efficacy against notoedres mange for its Revolution&#xAE; Plus which is a topical combination product to treats ticks, fleas, ear mites, lice and gastrointestinal worms and prevents heartworm disease in cats. It also received approval for Valcor&#x2122;, Fostera&#xAE; Gold PCV, Poulvac Maternavac&#xAE;, and Synovex&#xAE; Primer&#x2122; in different regions, catering to a variety of concerns.
Further, in September, ZTS expanded its India Capability Center in Hyderabad, India, which will play a crucial role in driving its digital transformation, improving efficiencies, and advancing its vision to shape the future of animal care.
Shares of ZTS have surged 2.7% over the past six months to close its last trading session at $176.94.
Let's look at factors that could influence ZTS' performance in the upcoming months.
Robust Financials
ZTS' revenue increased 11% year-over-year to $2.39 billion during the third quarter that ended September 30, 2024. Its non-GAAP gross profit grew 11.4% from the year-ago value to $1.69 million. The company's income before the provision of taxes on income of $874 million indicates a growth of 21.9% from the prior year's quarter.
In addition, non-GAAP net income attributable to Zoetis came in at $716 million and $1.58 per share, up 13.8% and 16.2% year-over-year, respectively.
Building on the company's strong momentum through the three quarters of the year, ZTS raised its financial guidance for the full year 2024. The company now projects revenue between $9.20 billion and $9.30 billion, reflecting operational growth of 10% to 11%. ZTS' adjusted EPS is projected at $5.86 to $5.92. Also, its adjusted net income is expected to be $2.67 billion to $2.69 billion.
Solid Historical Growth
ZTS' revenue and <a href="https://www.investopedia.com/terms/e/ebitda.asp">EBITDA</a> have grown at respective CAGR of 6.3% over the past three years. The company's EBIT has increased at a CAGR of 6.8% over the same timeframe, while its net income and EPS have improved at CAGRs of 7% and 8.6%, respectively.
Furthermore, the company's tangible book value and levered free cash flow have grown at CAGRs of 47.8% and 9.1% over the past three years, respectively.
Favorable Analyst Estimates
Analysts expect ZTS' revenue for the fourth quarter (ending December 2024) to increase 5.2% year-over-year to $2.33 billion. The consensus EPS estimate of $1.38 for the ongoing quarter indicates an 11.4% year-over-year improvement. Moreover, ZTS has an impressive earnings surprise history, having topped the consensus revenue estimates in each of the trailing four quarters.
For the fiscal year ending December 2024, the company's revenue and EPS are expected to grow 8.5% and 10.4% year-over-year to $9.27 billion and $5.88, respectively. Additionally, Street expects its revenue and EPS for the fiscal year 2025 to increase 5.1% and 9.2% year-over-year to $9.74 billion and $6.41, respectively.
High Profitability
ZTS' trailing-12-month gross profit margin of 70.09% is 20.6% higher than the industry average of 58.10%. Its trailing-12-month EBITDA margin and levered FCF margin of 41.13% and 20.46% are significantly higher compared to the industry averages of 5.54% and 2.33%, respectively. Similarly, its trailing-12-month CAPEX/Sales of 6.96% is 121.1% higher than the industry average of 3.15%.
POWR Ratings Reflect Promise
ZTS' solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, translating to a Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. ZTS has a B grade for Quality and Sentiment, consistent with its higher-than-industry profitability and optimistic analyst estimates.
In addition, the stock also has a B grade for Stability, which is justified by its 5-year beta of 0.90.
ZTS is ranked #21 in the 155-stock <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry.
Beyond what I have stated above, we have also given ZTS grades for Value, Momentum, and Growth. Get access to all the ZTS ratings <a href="https://stocknews.com/stock/ZTS/">here</a>.
Bottom Line
ZTS is a leading animal health company that is engaged in the formation and delivery of animal health medicines. The company has maintained a strong industry position through its innovative products and solutions, catering to diverse concerns. The company has maintained a strong financial front, and with its strategic expansion in different regions, it is poised for continued growth.
Zoetis' long-term prospects are also robust, as are its diverse product offerings and successful acceptance of its products from authorities and customers, as reflected by its strong operational revenue growth.
Therefore, with solid financial performance, accelerating profitability, reliable dividends, and a promising growth outlook, ZTS could be an ideal portfolio addition for now.
How Does Zoetis Inc. (ZTS) Stack Up Against Its Peers?
While ZTS has an overall POWR Rating of B, investors could also check out these other stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry with A (Strong Buy) or B (Buy) ratings: Bristol-Myers Squibb Co. (<a href="https://stocknews.com/stock/BMY/">BMY</a>), Supernus Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/SUPN/">SUPN</a>), and Taro Pharmaceutical Industries Ltd. (<a href="https://stocknews.com/stock/TARO/">TARO</a>).
For exploring more A and B-rated industrial stocks, <a href="https://stocknews.com/category/industrial-machinery/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZTS shares were trading at $175.86 per share on Wednesday afternoon, down $1.08 (-0.61%). Year-to-date, ZTS has declined -10.02%, versus a 28.79% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zts-bmy-supn-taro-is-zoetis-leading-the-charge-in-animal-health-innovation/>Is Zoetis Leading the Charge in Animal Health Innovation?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Zoetis Leading the Charge in Animal Health Innovation?

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zoetis (ZTS – Research Report), Walgreens Boots Al...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Walgreens Boots Alliance (WBA) and Bicycle Therapeutics (BCYC)

The Wall Street Journal Vs. Zoetis

Zoetis (ZTS) reported strong financial results for the last reported quarter. Amid the growing attention and concern on animal health and care, ZTS' diverse product portfolio stands to benefit significantly from its continuous product innovations. So, should you buy this innovative pharmaceutical stock considering the current trends? Read more to find out... Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>) is a leading pharmaceutical company that emphasizes the discovery, development, manufacturing, and commercialization of animal health medicines, vaccines, and diagnostic products and services worldwide. The company's last reported financial reports beat the analysts' estimates. Its revenue of $2.39 billion surpassed the consensus estimate of $2.29 billion.
The company's strong revenue growth was driven primarily by sales of companion animal products, up 18% year-over-year, drawn by monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela&#xAE; for dogs, and Solensia&#xAE; for cats. Further, Simparica Trio&#xAE;, Apoquel&#xAE;, and Cytopoint&#xAE; also contributed to the growth during the quarter.
Recently, ZTS received approval in China for Apoquel&#xAE; Chewable (oclacitinib chewable tablet) for controlling pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs. Also, Revolution&#xAE; Plus (selamectin/sarolaner), a topical combination product received approval in the EU for an additional claim related to efficacy against notoedres mange.
Besides, Zoetis is also working strategically to expand its operations in diverse locations and strategically divestiture in order to optimize its scope of operations. The company expanded its presence in India with a Capability Center in Hyderabad. The Center will play a vital role in driving digital transformation and improving efficiencies.
Also, it completed the divestiture of its medicated feed additive (MFA) product portfolio, certain water-soluble products, and related assets to Phibro Animal Health. Such well-thought-out measures will enhance the company's future growth and prosperity. Further, the company's product demand will grow exponentially with more people concerned about animal health and surging market demand.
The company raised its financial guidance for the full year 2024. ZTS forecasts revenue of $9.20 billion to $9.30 billion, representing operational growth of 10% to 11%. Its adjusted EPS is projected to be between $5.86 and $5.92. Further, the company's adjusted net income is expected to be $2.67 billion - $2.69 billion.
Shares of ZTS have plunged 4.2% over the past six months to close the last trading session at $164.70.
Let's look at factors that could influence ZTS' performance in the upcoming months.
Stable Financials
For the third quarter that ended September 30, 2024, ZTS reported revenue of $2.39 billion, up 11% from the prior year's quarter. Its non-GAAP gross profit increased 11.4% from the year-ago value to $1.69 billion.
Furthermore, non-GAAP net income attributable to Zoetis amounted to $716 million or $1.58 per share, reflecting increases of 13.8% and 16.2% from the prior-year quarter, respectively.
Impressive Historical Growth
ZTS' revenue and <a href="https://www.investopedia.com/terms/e/ebitda.asp">EBITDA</a> have grown at a CAGR of 6.3% over the past three years, respectively. Its EBIT increased at a CAGR of 6.8% over the same period, while the company's net income and EPS grew at respective CAGRs of 7% and 8.6% over the same time frame.
Also, the company's tangible book value and levered free cash flow increased at CAGRs of 47.8% and 9.1% over the same timeframe.
Favorable Analyst Estimates
Analysts expect ZTS' revenue for the fourth quarter (ending December 2024) to come in at $2.33 billion, indicating an increase of 5.2% year-over-year, and the consensus EPS estimate of $1.36 for the same period indicates an improvement of 9.4% year-over-year. Moreover, the company has surpassed the consensus revenue estimates in all of the trailing four quarters.
For the fiscal year (ending December 2024), the company's EPS is anticipated to grow 10.5% year-over-year to $5.88, while its revenue is expected to increase 8.5% year-over-year to $9.27 billion. In addition, Street expects its revenue and EPS for the fiscal year 2025 to grow 5% and 9% from the prior year to $9.73 billion and $6.41, respectively.
High Profitability
ZTS' trailing-12-month EBIT margin of 36.48% is significantly higher than the 2.76% industry average. Its trailing-12-month gross profit margin of 70.09% is 20.4% higher than the industry average of 58.23%. Likewise, the stock's trailing-12-month levered FCF margin of 20.46% is 891.7% higher than the industry average of 2.06%.
POWR Ratings Reflect Promise
ZTS' robust fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, translating to a Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. ZTS has a B grade for Sentiment and Quality, which is consistent with its encouraging analysts' expectations and higher-than-industry profitability.
Also, with a 5-year beta of 0.90, the stock has earned a B grade for Stability.
ZTS is ranked #21 among the 149 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry.
Beyond what I have stated above, we have also given ZTS grades for Growth, Value, and Momentum. <a href="https://stocknews.com/stock/ZTS/">Click here</a> to access all ZTS ratings.
Bottom Line
ZTS is a leading animal health-focused pharmaceutical company. Its innovative products and broadening product choices are attracting more and more customers, as is reflected in its strong revenue growth across different segments. Also, the company's strategic initiatives and measures are adding more opportunities for its operations and scale.
Considering the company's strong financials, accelerating profitability, and robust growth outlook, it could be wise to invest in ZTS.
How Does Zoetis Inc. (ZTS) Stack Up Against Its Peers?
While ZTS has an overall POWR Rating of B, investors could also check out these other stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry with A (Strong Buy) or B (Buy) ratings: Bristol-Myers Squibb Co. (<a href="https://stocknews.com/stock/BMY/">BMY</a>), Supernus Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/SUPN/">SUPN</a>), and Taro Pharmaceutical Industries Ltd. (<a href="https://stocknews.com/stock/TARO/">TARO</a>).
For exploring more A and B-rated medical stocks, <a href="https://stocknews.com/category/pharmaceuticals/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZTS shares were trading at $164.93 per share on Thursday afternoon, up $0.23 (+0.14%). Year-to-date, ZTS has declined -15.61%, versus a 28.24% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/zts-bmy-supn-taro-is-zoetis-a-smart-investment-in-the-pharmaceuticals-sector/>Is Zoetis a Smart Investment in the Pharmaceuticals Sector?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Zoetis a Smart Investment in the Pharmaceuticals Sector?

Healthcare innovators are gaining momentum as they address critical challenges in biotechnology, medical devices, and pharmaceuticals. Amid this backdrop, you might consider keeping an eye on three healthcare innovators, Zoetis (ZTS), Immatics N.V. (IMTX), and Esperion Therapeutics (ESPR), which have robust upside potential. Read on… Healthcare innovation is at the forefront of investment trends as companies push boundaries in biotechnology, medical devices, and pharmaceuticals. These innovators are developing groundbreaking solutions to address chronic diseases, improve patient outcomes, and streamline medical processes.
Below, I have highlighted three healthcare innovators: Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>), Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>), and Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>), which are well-positioned for potential upside gain.
Biotechnology companies are leading the charge, leveraging gene editing and immunotherapy to combat diseases once considered incurable, with the focus being on innovation-driven growth. According to the American Society of Gene and Cell Therapy (ASGCT), <a href="https://www.labiotech.eu/more-news/biotech-2024-retrospective/">a total of 32 gene therapies and 34 RNA therapies have been approved</a> globally by the third quarter of 2024.
Moreover, innovation in healthcare is active across multiple sectors. With that being said, medical device manufacturers are also an area of focus as they introduce new technologies to improve diagnostics and surgical procedures. <a href="https://www.inpart.io/blog/17-top-healthcare-innovations-2023">From wearable health monitors to robotic surgery systems</a>, these innovations are driving demand and revenue.
The global healthcare services market is projected to reach <a href="https://www.verifiedmarketresearch.com/product/healthcare-services-market/">$22.57 trillion by 2031</a>, growing at a CAGR of 8.3%. With robust pipelines and strategic partnerships, healthcare companies are well-positioned to thrive in an evolving healthcare landscape.
Given these factors, let's delve deeper into the fundamentals of the above-mentioned stocks:
Zoetis Inc. (<a href="https://stocknews.com/stock/ZTS/">ZTS</a>)
ZTS is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health. 
On December 12, demonstrating its commitment to returning value to shareholders, the company declared a quarterly dividend of $0.50 per share, an increase of 16%, payable on March 4, 2025, to shareholders of record at the close of business on January 21, 2025.
ZTS pays an annual dividend of $2, which translates to a yield of 1.21% at the current share price. Its four-year average dividend yield is 0.73%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 20% over the past three years.
On September 26, ZTS and Danone SA together announced a joint business development plan to drive sustainable practices on dairy farms through the power of genetics for healthier cows. This strategic partnership aims to innovate the dairy industry's approach to breeding for sustainability with ZTS' genetic testing solutions.
During the third quarter that ended on September 30, 2024, ZTS' <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> increased 11% year-over-year to $2.39 billion. It posted a non-GAAP gross profit of $1.69 billion, indicating an 11.4% increase from the prior-year quarter. In addition, its non-GAAP net income and non-GAAP EPS amounted to $716 million and $1.58, reflecting increases of 13.8% and 16.2% year-over-year, respectively.
The consensus revenue estimate of $2.33 billion for the fiscal fourth quarter (ending December 2024) represents a 5.2% increase year-over-year. The consensus EPS estimate of $1.36 for the same quarter indicates a 9.4% improvement year-over-year. The company has an excellent surprise history; it surpassed the consensus revenue estimates in each of the trailing four quarters.
ZTS' EBIT has grown at CAGRs of 6.8% and 9.8% over the past three and five years, respectively. Likewise, the company's diluted EPS has increased at a CAGR of 11.9% over the past three years.
ZTS shares have surged marginally intraday to close the last trading session at $164.70.
The 12-month median price target of $211 indicates <a href="https://www.tipranks.com/stocks/zts/forecast">a 28.1% upside potential</a> from the last closing price. The price targets range from a low of $180 to a high of $248.
ZTS' <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
ZTS has a B grade for Stability, Sentiment, and Quality. It is ranked #21 out of 149 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/ZTS/">Click here</a> to see the additional ratings for ZTS (Growth, Value, and Momentum).
Immatics N.V. (<a href="https://stocknews.com/stock/IMTX/">IMTX</a>)
Based in Tübingen, Germany, IMTX, a clinical-stage biopharmaceutical company, is focused on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer. It is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities.
In the fiscal third quarter that ended on September 30, 2024, IMTX's revenue from collaboration agreements increased 753.2% year-over-year to €50.56 million ($52.54 million). As of September 30, 2024, IMTX's cash reached €189.19 million ($196.62 million), with total assets amounting to €577.23 million ($599.88 million) as of September 30, 2024.
Analysts expect IMTX's revenue for the fiscal year (ending December 2024) to grow 107.4% year-over-year to $121.56 million. 
Over the past three years, IMTX's revenue and total assets grew at CAGRs of 59.5% and 42.6%, respectively.
The stock has gained marginally intraday to close the last trading session at $7.10.
Based on Wall Street analysts offering 12-month price targets for IMTX in the last three months, <a href="https://www.tipranks.com/stocks/imtx/forecast">the average target price is $16.92</a>, indicating a 138.3% change from the last price.
IMTX's stance is apparent in its POWR Ratings. The stock has a B grade for Value and Sentiment. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #55. <a href="https://stocknews.com/stock/IMTX/">Click here</a> to see the additional IMTX ratings (Growth, Momentum, Stability, and Quality).
Esperion Therapeutics, Inc. (<a href="https://stocknews.com/stock/ESPR/">ESPR</a>)
ESPR, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL and NEXLIZET tablets for treating primary hyperlipidemia in adults who require additional LDL-C lowering.
On December 12, ESPR announced that it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe) in Israel.
In this agreement, ESPR will receive an upfront payment and near-term milestones along with tiered royalties. This agreement should also expand ESPR's global reach for cardiovascular and cardiometabolic diseases.
On September 3, ESPR announced additional commercial and medicare coverage for NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE; (bempedoic acid and ezetimibe). This addition provides access to more than 65% of medicare lives and more than 92% of commercially insured lives, allowing the healthcare providers to prescribe it to primary and secondary prevention patients easily.
For the nine-month period that ended on September 30, 2024, ESPR's total revenues increased 213% year-over-year to $263.20 million. Its income from operation came in at $58.82 million compared to a year-ago net loss of $113.19 million. The company's cash and cash equivalents and total assets came in at $144.72 million and $314.11 million as of September 30, 2024.
Street expects ESPR's revenue for the fiscal fourth quarter (ending December 2024) to increase 92.7% year-over-year to $62.14 million. In addition, it surpassed the revenue estimates in three of the trailing four quarters, which is promising.
Moreover, ESPR's revenue has grown at CAGRs of 59.6% and 14.9% over the past three and five years, respectively. In addition, its total assets increased at 11.7% CAGR over the past three years.  
Over the past three months, the stock has surged 39.4%, closing the last trading session at $2.30.
Based on Wall Street analysts offering 12-month price targets for ESPR in the last three months, <a href="https://www.tipranks.com/stocks/espr/forecast">the average target price is $6.86</a>, indicating a 198.3% change from the last price, with a high forecast of $16 and a low forecast of $2.05.
ESPR's fundamentals are reflected in its POWR Ratings. The stock has a B grade for Growth, Value, and Quality. It is ranked #39 out of 335 stocks in the Biotech industry.
Beyond what is stated above, we've also rated ESPR for Momentum, Stability, and Sentiment. Get all ESPR's ratings <a href="https://stocknews.com/stock/ESPR/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ZTS shares were trading at $165.04 per share on Thursday afternoon, up $0.34 (+0.21%). Year-to-date, ZTS has declined -15.55%, versus a 28.18% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/zts-imtx-espr-3-healthcare-innovators-with-analyst-endorsed-upside/>3 Healthcare Innovators with Analyst-Endorsed Upside</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Innovators with Analyst-Endorsed Upside

ALLE

APLO

AVGO

BCPC

BCYC

BSVN

CABO

CARR

CBSH

CCBG

CINF

CSGS

ENSG

EPRT

ERIE

ESPR

EVRG

EXPO

FRME

GOLF

IMTX

INVH

JJSF

JKHY

KFRC

KLIC

LAND

MBWM

NDAQ

NRIM

ODFL

OFLX

OLED

OTEX

QCOM

RBCAA

SAMG

SEIC

SUPN

SWBI

TARO

TCBK

UBCP

VCTR

VICI

WDFC

Press Releases

Zoetis to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Zoetis to Host Webcast and Conference Call on Third Quarter 2024 Financial Results

Zoetis and Danone Announce Strategic Partnership to Pioneer Sustainable Innovation in Dairy Farming Using the Power of Genetics

Zoetis Declares Fourth Quarter 2024 Dividend

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products

Zoetis Announces Third Quarter 2024 Results

Zoetis to Participate in Jefferies London Healthcare Conference

Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference

Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase

PAHC

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Comments

Zoetis

매도 수량

Zoetis (NYSE:ZTS) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌